LAVAL, Quebec, June 19, 2017 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
("Valeant") today announced Arthur J.
Shannon has joined the company as senior vice president,
head of Investor Relations and Communications.
Mr. Shannon has more than 20 years of experience in the field of
investor relations. He joins Valeant from Perrigo, Inc., where he
served as vice president of Global Corporate Affairs and European
Investor Relations. Prior to that, he held roles of increasing
importance in investor relations at Thomson Financial and Dynegy,
Inc.
"We're delighted to welcome Art
Shannon to the Valeant team," said Paul S. Herendeen, executive vice president,
Finance, and chief financial officer, Valeant. "With his in-depth
knowledge of the pharmaceutical industry and proven track record in
investor relations and strategic communications, Art will quickly
become an important conduit between Valeant and the business
community."
With the addition of Mr. Shannon, Scott
Hirsch will assume the role of senior vice president, chief
business strategy officer. Mr. Hirsch will now dedicate his time to
key corporate initiatives, including the development and execution
of a five-year strategic plan.
Arthur J. Shannon
(Biography)
Arthur J. Shannon joined Valeant
Pharmaceuticals International, Inc. as senior vice president and
head of Investor Relations and Communications on June 19, 2017. He previously held the role of
vice president of Global Corporate Affairs and European Investor
Relations for 11 years at Perrigo. Prior to that, Mr. Shannon
served as vice president of Investor Relations for the
Energy/Utility division at Thomson Financial, and earlier in his
career, he was a senior director of Investor Relations at Dynegy,
Inc. Mr. Shannon has received several accolades throughout his
career, including the IR Magazine US Awards' Top IR Professional
award in 2012. He holds a Bachelor of Science in Business
Administration: Finance from Georgetown
University.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements which
may generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in Valeant's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements
speak only as of the date hereof. Valeant undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
Investor Contact:
Elif
McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media Contact:
Lainie
Keller
lainie.keller@valeant.com
908-927-0917
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-appoints-arthur-j-shannon-as-senior-vice-president-head-of-investor-relations-and-communications-300476211.html
SOURCE Valeant Pharmaceuticals International, Inc.